Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation
Brian A. Keller(University of Ottawa), John C. Bell(Ottawa Hospital), Jean‐Simon Diallo(University of Ottawa), Harold Atkins(University of Ottawa), Catia Cemeus(Ottawa Hospital), Michael Ong(Ottawa Hospital), Bernard Lo(University of Toronto), Brian J. Laight(Ottawa Hospital), Julia Petryk(Ottawa Hospital), Carolyn Nessim(University of Ottawa), Marie-Ève Wedge(University of Ottawa), Oliver Varette(University of Ottawa), Carolina S. Ilkow(Ottawa Hospital), Benjamin McSweeney(Ottawa Hospital), Roberto A. Chica(University of Ottawa), Bruce F. Burns(Ottawa Hospital), Aron Broom(University of Ottawa)
Cited by 4
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816